Viral Antigens
Viral Antigens(病毒抗原)
A viral Antigen is an antigen with multiple antigenicities that is protein in nature, strain-specific, and closely associated with the virus particle. A viral antigen is a protein encoded by the viral genome.A viral protein is an antigen specified by the viral genome that can be detected by a specific immunological response.
Viruses are infectious pathogens that cause serious diseases & major threats for global public health, such as influenza, hepatitis, & AIDS. Virus is a sub-micrometer particle that has DNA or RNA packed in a shell called capsid. Viral antigens protrude from the capsid and often fulfill important function in docking to the host cell, fusion, and injection of viral DNA/RNA. Antibody-based immune responses form a first layer of protection of the host from viral infection; however, in many cases a vigorous cellular immune response mediated by T-cells and NK-cells is required for effective viral clearance. When cellular immunity is unable to clear the virus, the infection can become chronic, and serum antibodies to the viral pathogen are used as first indicator for the diagnosis of the disease.
ELISAs provide a valuable tool in the detection and diagnosis of virus infection. The ability to produce recombinant viral proteins will ensure that future ELISAs are safe, specific and rapid. Even when a virus cannot be cultured, provided gene sequence is available, it is possible to rapidly respond to emerging viruses and new viral strains of existing pathogens.
Recombinant viral antigens contain part of viral sequence meaning that the recombinant antigen contains a region which can be recognized by different antibodies produced by different individuals. This reduces the risk of false negatives which can occur with synthetic peptides, which contain only a small portion of the entire protein. If an individual infected with a viral antigen makes antibodies to a part of the protein not included in the synthetic peptides, a false negative results.
Recombinant viral protein usually contains a fusion protein/partner which produces superior attachment to assay surfaces such as wells. For this reason, smaller amounts of recombinant protein will produce the same results as larger amounts of unfused protein. The choice of fusion partner prevents false positives, allowing superior adhesion without incorrect results.
Recombinant Viral proteins are expressed in bacteria, yeast, mammalian cells, and viruses. E. Coli cells were first to be used for this purpose but the expressed proteins were not glycosylated, which was a major drawback since many of the immunogenic proteins of viruses such as the envelope glycoproteins, were glycosylated. Nevertheless, in many instances, it was demonstrated that the non-glycosylated protein backbone was just as immunogenic. The obvious advantage of recombinant viral antigens is that they are available in unlimited quantities and the production and quality control processes is simple.
Advantages of defined using recombinant viral antigens:
1. Production and quality control is simple.
2. No nucleic acids or other viral or external proteins, therefore less toxic.
3. Safer in cases where viruses are oncogenic or establish a persistent infection.
4. Feasible even if virus cannot be cultivated
Disadvantages:
1. May be less immunogenic than conventional inactivated whole-virus vaccines.
2. Requires adjuvant .
3. Fails to elicit CMI.
Facts about Viral Antigens:
1. A Viral Protein Mimics its Way into cells.
2. Viral Protein Helps Infected T Cells Stick To Uninfected Cells.
3. The Viral Protein A238L Inhibits Cyclooxygenase-2 Expression through a Nuclear Factor of Activated T Cell-dependent Trans-activation Pathway.
4. Viral Protein is an effective preventative against ear infection.
5. HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore.
6. The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function.
7. Antigen-presenting cells from calves persistently infected with bovine viral diarrhea virus, a member of the Flaviviridae, are not compromised in their ability to present viral antigen.
8. There is a difference in the distribution and spread of a viral antigen, development of lesions and correlation between presence of viral antigen and lesions.
9. The absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells is a strategy to avoid complement-mediated lysis.
10. Viral Protein Influences Key Cell-signaling Pathway.
11. A viral protein produced by cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.
12. Protection by recombinant viral proteins against a respiratory virulent avian metapneumovirus has been achieved.
13. Viral O-acetylesterases are found in influenza C viruses and Corona-viruses. Viral O-acetylesterases remove cellular receptors from the surface of target cells which destroys the receptor. Recombinant viral O-acetylesterases derived from Sf9 insect cells as chimeric proteins fused to eGFP specifically hydrolyze 9-O-acetylated sialic acids, while that of sialodacryoadenitis virus, a rat coronavirus related to mouse hepatitis virus, is specific for 4-O-acetylated sialic acid. The recombinant esterases were shown to specifically de-O-acetylate sialic acids on glycoconjugates. The recombinant viral proteins can be used to unambiguously identify O-acetylated acids.
- Borrelia(28)
- Chagas(3)
- Chikungunya(7)
- Chlamydia(10)
- Cytomegalo(8)
- Dengue(50)
- Ebola(4)
- EBV(13)
- Encephalitis(8)
- Feline Leukemia Virus(1)
- Hantavirus(1)
- HBsAg(8)
- Helicobacter Pylori(3)
- Hepatitis A(15)
- Hepatitis B(10)
- Hepatitis C(85)
- Hepatitis D(1)
- Hepatitis E(5)
- Herpes(11)
- HERV-K(1)
- HIV(152)
- HTLV(6)
- Influenza(73)
- Lassa(2)
- Malaria(77)
- Mumps(1)
- Mycoplasma(4)
- Norovirus(4)
- Papillomavirus(5)
- Parvovirus(3)
- Rubella(3)
- S. Typhi(5)
- SARS(85)
- Shiga Like Toxin(2)
- Toxoplasma(9)
- Treponema(16)
- Varicella(3)
- West Nile(2)
- Zika(14)
Viral Antigens 相关产品(718)
- GC65034IbalizumabCAS: 680188-33-4
Ibalizumab (TMB-355) 是一种人源化 IgG4 单克隆抗体,通过与 CD4 受体结合来阻止 HIV 细胞进入。Ibalizumab 具有用于 HIV-1 感染研究的潜力。
- GC650853'-Azido-3'-deoxy-5-methylcytidineCAS: 1282040-14-5纯度: >99.00%
3'-Azido-3'-deoxy-5-methylcytidine (CS-92) 是一种有效的异嗜性小鼠白血病相关逆转录病毒 (XMRV) 抑制剂,作用于 MCF-7 细胞,CC50 为 43.5 μM。3'-Azido-3'-deoxy-5-methylcytidine (CS-92) 作用于外周血单核细胞 (PBM),抑制 HIV-1 逆转录酶,EC50 为 0.06 μM。
- GC65158HIV-1 inhibitor-8CAS: 2826996-78-3纯度: >98.00%
HIV-1 inhibitor-8 是一种具有口服活性、低毒和有效的 HIV -1 非核苷逆转录酶抑制剂 (NNRTI)。HIV-1 inhibitor-8 对各种 HIV -1 菌株产生有效的抗病毒活性 (EC50=4.44~54.5 nM)。HIV-1 inhibitor-8 对 WT HIV-1 逆转录酶的 IC50 为 0.081 μM。
- GC65256HIV-1 inhibitor-6CAS: 1821309-39-0纯度: >98.00%
HIV-1 inhibitor-6 (compound 9) 是一种基于二杂芳基酰胺的化合物,是一种有效的 HIV-1 pre-mRNA 选择性剪接抑制剂。HIV-1 inhibitor-6 可以阻断 HIV 复制。HIV-1 inhibitor-6 对野生型 HIV-1IIIB (亚型 B,X4-tropic) 和 HIV-1 97USSN54 (亚型 A,R5-tropic) 具有活性,EC50 值分别为 0.6 μM 和 0.9 μM。HIV-1 inhibitor-6 抑制对靶向 HIV 逆转录酶、蛋白酶、整合酶和辅助受体 CCR5 的药物耐药的 HIV 菌株,EC50 范围为 0.9 至 1.5 μM。
- GC65363(1R)-Tenofovir amibufenamideCAS: 1571076-15-7
(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 是 Tenofovir amibufenamide 的异构体,是一种口服活性抗病毒药物。(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 是一个 HIV 病毒感染的抑制剂和乙型肝炎病毒的抑制剂 ( HBV )。(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 可用于 HIV 感染、乙肝研究。
- GC66467ClaficapavirCAS: 2055732-24-4纯度: >99.00%
Claficapavir (A1752) 是一种特异的核衣壳蛋白 (nucleocapsid protein) 抑制剂,IC50 约为1μM。Claficapavir 与 HIV-1 NC(Kd=20 nM) 强烈结合,从而抑制 NC 的伴侣特性,并导致对 HIV-1 具有良好的抗病毒活性。
- GC68023HIV-1 inhibitor-48CAS: 374067-85-3纯度: >99.00%
HIV-1 inhibitor-48 (compound 13o) 是一种新型的非核苷逆转录酶抑制剂 (NNRTI),具有抗 HIV-1 活性。
- GC68678APOBEC3G-IN-1CAS: 14261-92-8纯度: >96.00%
APOBEC3G-IN-1 (MN136.0185) 是一种强效的 HIV 抑制剂,靶向 APOBEC3G。
- GC68719AZT triphosphate tetraammonium纯度: >99.00%
AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) tetraammonium 是一种 Zidovudine (AZT) 的活性三磷酸酯代谢产物。AZT triphosphate tetraammonium 具有抗逆转录病毒的活性,并抑制 HIV 复制。AZT triphosphate tetraammonium 还可抑制 HBV 的 DNA 聚合酶。AZT triphosphate tetraammonium 可激活线粒体介导的凋亡 (apoptosis) 途径。
- GC68930Cys-TAT(47-57) TFA纯度: >97.00%
Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) 是能穿透细胞的富含精氨酸的十二肽,是 HIV-1 反式激活蛋白衍生物。
- GC69180Glycolithocholic acid 3-sulfateCAS: 15324-64-8纯度: >99.00%
Glycolithocholic acid 3-sulfate (SLCG) 是一种胆汁酸衍生物和甘胆酸的代谢物。Glycolithocholic acid 3-sulfate 抑制 HIV-1 的复制。Glycolithocholic acid 3-sulfate 可用于研究 HIV 感染和胆囊疾病。
- GC69230HIV-1 inhibitor-45CAS: 2677762-43-3纯度: >99.00%
HIV-1 inhibitor-45 (compound IA-6) 是一种有效的 HIV-1 RNase H 抑制剂,IC50 为 0.067 μM。HIV-1 inhibitor-45 显示出抗病毒活性。
- GC70647Emtricitabine triphosphate tetrasodium saltCAS: 1188407-46-6纯度: >99.00%
Emtricitabine triphosphate tetrasodium salt是恩曲他滨三磷酸盐的四钠盐形式。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC65034 | Ibalizumab | 680188-33-4 | - | |
Ibalizumab (TMB-355) 是一种人源化 IgG4 单克隆抗体,通过与 CD4 受体结合来阻止 HIV 细胞进入。Ibalizumab 具有用于 HIV-1 感染研究的潜力。 | ||||
| GC65085 | 3'-Azido-3'-deoxy-5-methylcytidine | 1282040-14-5 | >99.00% | |
3'-Azido-3'-deoxy-5-methylcytidine (CS-92) 是一种有效的异嗜性小鼠白血病相关逆转录病毒 (XMRV) 抑制剂,作用于 MCF-7 细胞,CC50 为 43.5 μM。3'-Azido-3'-deoxy-5-methylcytidine (CS-92) 作用于外周血单核细胞 (PBM),抑制 HIV-1 逆转录酶,EC50 为 0.06 μM。 | ||||
| GC65134 | HIV-IN-6 | 301357-74-4 | >98.00% | |
HIV-IN-6 是一种 HIV-Ⅰ 病毒复制抑制剂,通过靶向与病毒 Nef 蛋白相互作用的 Src 家族激酶 (SFK) (如 Hck) 而起作用。 | ||||
| GC65158 | HIV-1 inhibitor-8 | 2826996-78-3 | >98.00% | |
HIV-1 inhibitor-8 是一种具有口服活性、低毒和有效的 HIV -1 非核苷逆转录酶抑制剂 (NNRTI)。HIV-1 inhibitor-8 对各种 HIV -1 菌株产生有效的抗病毒活性 (EC50=4.44~54.5 nM)。HIV-1 inhibitor-8 对 WT HIV-1 逆转录酶的 IC50 为 0.081 μM。 | ||||
| GC65256 | HIV-1 inhibitor-6 | 1821309-39-0 | >98.00% | |
HIV-1 inhibitor-6 (compound 9) 是一种基于二杂芳基酰胺的化合物,是一种有效的 HIV-1 pre-mRNA 选择性剪接抑制剂。HIV-1 inhibitor-6 可以阻断 HIV 复制。HIV-1 inhibitor-6 对野生型 HIV-1IIIB (亚型 B,X4-tropic) 和 HIV-1 97USSN54 (亚型 A,R5-tropic) 具有活性,EC50 值分别为 0.6 μM 和 0.9 μM。HIV-1 inhibitor-6 抑制对靶向 HIV 逆转录酶、蛋白酶、整合酶和辅助受体 CCR5 的药物耐药的 HIV 菌株,EC50 范围为 0.9 至 1.5 μM。 | ||||
| GC65363 | (1R)-Tenofovir amibufenamide | 1571076-15-7 | - | |
(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 是 Tenofovir amibufenamide 的异构体,是一种口服活性抗病毒药物。(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 是一个 HIV 病毒感染的抑制剂和乙型肝炎病毒的抑制剂 ( HBV )。(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 可用于 HIV 感染、乙肝研究。 | ||||
| GC65903 | NBD-14270 | 2411819-82-2 | >98.00% | |
NBD-14270,一种吡啶类似物,是一种有效的 HIV-1 进入拮抗剂,对 50 株 HIV-1 假型病毒的 IC50 为 89 nM。NBD-14270 与 HIV-1 gp120 结合并显示出强大的抗病毒活性 (EC50<200 nM)。NBD-14270 显示低细胞毒性 (CC50>100 μM)。 | ||||
| GC65905 | NBD-14189 | 2234273-72-2 | >99.00% | |
NBD-14189 是一种有效的 HIV-1 进入拮抗剂,对 HIV-1HXB2 假病毒的 IC50 为 89nM。NBD-14189 与 HIV-1 gp120 结合并显示出强大的抗病毒活性 (EC50<200 nM)。 | ||||
| GC65963 | AzddMeC | 87190-79-2 | >98.00% | |
AzddMeC (CS-92) 是一种抗病毒核苷类似物,也是一种有效的,选择性的,具有口服活性的 HIV-1 逆转录酶和 HIV-1 复制的抑制剂。在感染 HIV-1 的人类 PBM 细胞和感染 HIV-1 的人类巨噬细胞中,AzddMeC 的 EC50 值分别为 9 nM 和 6 nM。 | ||||
| GC66051 | Cabotegravir sodium | 1051375-13-3 | >98.00% | |
An HIV-1 integrase inhibitor | ||||
| GC66467 | Claficapavir | 2055732-24-4 | >99.00% | |
Claficapavir (A1752) 是一种特异的核衣壳蛋白 (nucleocapsid protein) 抑制剂,IC50 约为1μM。Claficapavir 与 HIV-1 NC(Kd=20 nM) 强烈结合,从而抑制 NC 的伴侣特性,并导致对 HIV-1 具有良好的抗病毒活性。 | ||||
| GC68023 | HIV-1 inhibitor-48 | 374067-85-3 | >99.00% | |
HIV-1 inhibitor-48 (compound 13o) 是一种新型的非核苷逆转录酶抑制剂 (NNRTI),具有抗 HIV-1 活性。 | ||||
| GC68449 | CA inhibitor 1 | 2189684-45-3 | - | |
CA inhibitor 1 (GS-6207 analog) 是一种有效的 HIV 衣壳抑制剂,可用于抑制 HIV。 | ||||
| GC68678 | APOBEC3G-IN-1 | 14261-92-8 | >96.00% | |
APOBEC3G-IN-1 (MN136.0185) 是一种强效的 HIV 抑制剂,靶向 APOBEC3G。 | ||||
| GC68719 | AZT triphosphate tetraammonium | - | >99.00% | |
AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) tetraammonium 是一种 Zidovudine (AZT) 的活性三磷酸酯代谢产物。AZT triphosphate tetraammonium 具有抗逆转录病毒的活性,并抑制 HIV 复制。AZT triphosphate tetraammonium 还可抑制 HBV 的 DNA 聚合酶。AZT triphosphate tetraammonium 可激活线粒体介导的凋亡 (apoptosis) 途径。 | ||||
| GC68930 | Cys-TAT(47-57) TFA | - | >97.00% | |
Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) 是能穿透细胞的富含精氨酸的十二肽,是 HIV-1 反式激活蛋白衍生物。 | ||||
| GC69180 | Glycolithocholic acid 3-sulfate | 15324-64-8 | >99.00% | |
Glycolithocholic acid 3-sulfate (SLCG) 是一种胆汁酸衍生物和甘胆酸的代谢物。Glycolithocholic acid 3-sulfate 抑制 HIV-1 的复制。Glycolithocholic acid 3-sulfate 可用于研究 HIV 感染和胆囊疾病。 | ||||
| GC69230 | HIV-1 inhibitor-45 | 2677762-43-3 | >99.00% | |
HIV-1 inhibitor-45 (compound IA-6) 是一种有效的 HIV-1 RNase H 抑制剂,IC50 为 0.067 μM。HIV-1 inhibitor-45 显示出抗病毒活性。 | ||||
| GC70056 | Trecovirsen | 153021-75-1 | >98.00% | |
Trecovirsen (GEM91) 是一种靶向 HIV gag 基因的反义寡核苷酸。 | ||||
| GC70227 | Clathrin-IN-1 | 1332879-52-3 | 不显示 | |
Clathrin-IN-1是一种选择性网格蛋白介导的内吞作用(CME)抑制剂。 | ||||
| GC70228 | SAMT-247 | 850715-59-2 | 不显示 | |
SAMT-247是一种杀微生物剂,可选择性地使病毒核衣壳蛋白NCp7失活,引起锌的排出并阻止RNA的衣壳化。 | ||||
| GC70579 | VK-1727 | - | >99.00% | |
VK-1727是EBNA1的选择性小分子抑制剂。 | ||||
| GC70647 | Emtricitabine triphosphate tetrasodium salt | 1188407-46-6 | >99.00% | |
Emtricitabine triphosphate tetrasodium salt是恩曲他滨三磷酸盐的四钠盐形式。 | ||||
| GC70661 | Dolutegravir-d3 | - | >99.00% | |
Dolutegravir-d3是氘标记的Dolutegravir。 | ||||
